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Abstract
Complex, multi-factorial secondary injury cascades are initiated following traumatic brain injury, 
which makes this a difficult disease to treat. The secondary injury cascades following the primary 
mechanical tissue damage, are likely where effective therapeutic interventions may be targeted. 
One promising therapeutic target following brain injury are mitochondria. Mitochondria are 
complex organelles found within the cell, which act as powerhouses within all cells by supplying 
ATP. These organelles are also necessary for calcium cycling, redox signaling and play a major 
role in the initiation of cell death pathways. When mitochondria become dysfunctional, there is a 
tendency for the cell to loose cellular homeostasis and can lead to eventual cell death. Targeting of 
mitochondrial dysfunction in various diseases has proven a successful approach, lending support 
to mitochondria as a pivotal player in TBI cell death and loss of behavioral function.
Within this mixed mini review/research article there will be a general discussion of mitochondrial 
bioenergetics, followed by a brief discussion of traumatic brain injury and how mitochondria play 
an integral role in the neuropathological sequelae following an injury. We will also give an 
overview of one relatively new TBI therapeutic approach, Methylene Blue, currently being studied 
to ameliorate mitochondrial dysfunction following brain injury. We will also present novel 
experimental findings, that for the first time, characterize the ex vivo effect of Methylene Blue on 
mitochondrial function in synaptic and non-synaptic populations of mitochondria.
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1. Introduction
1.1 Mitochondria, Powerhouse and Death Switch of Cells
Oxygen mediated respiration is vital for the survival of eukaryotes, and the functional role of 
respiration is assigned to a specialized organelle, the mitochondria. The role of mitochondria 
is not only that of the powerhouse of the cell, but is also a dynamic center for cellular 
homeostasis [1]. Newer information about mitochondria has shifted focus onto their crucial 
role in cellular plasticity and regulation. Owing to the complexity of the mammalian brain 
and its high dependency on oxygen, mitochondria play a very important role in ATP 
production and maintaining brain homeostasis.
The primary role of mitochondria is to generate ATP through the TCA cycle and oxidative 
phosphorylation, which is essential for driving neuronal functions including maintenance of 
the membrane potential and neurotransmission. Mitochondria contain a double membrane 
structure. The outer membrane is permeable allowing small molecules and ions to pass 
through via pore forming protein complexes like voltage dependent anion channels (VDAC) 
[2]. The inner membrane is almost impermeable and only selectively allows controlled 
transport of specific ions like K+, Na+ and Ca2+ and various metabolites like ADP, amino 
acids and pyruvate. The inner membrane is highly invaginated allowing it to maximize its 
surface area and house the electron transport chain (ETC), the FoF1 ATPase, and various 
other specific transporters [3]. Complex I (NADH/ubiquinone oxidoreductase) accepts 
electrons from NADH generated through the breakdown of the metabolic substrates like 
carbohydrates, lipids and proteins and transfer them to complex III via Coenzyme Q. The 
transport of electrons continue through complex III (cytochrome c reductase) through 
complex IV (cytochrome c oxidase) and ultimately reduces and splits molecular oxygen to 
generate two molecules of water (H2O). Each electron transfer step pumps two protons from 
matrix into the intermembrane space. This imbalance/gradient of protons across the inner 
membrane leads to the generation of electromotive force. This voltage difference drives back 
the movement of protons through FoF1 ATPase, which utilizes this electrochemical energy 
to drive the enzymatic phosphorylation of ADP to generate ATP [3].
In the past few decades mitochondria have gained special attention for their role in 
apoptosis, cell signaling, cell cycle regulation, Ca2+ homeostasis, and ROS production. 
Mitochondria play a vital role as a biological switch that determines the fate of the cell 
under stress [4]. They trigger apoptosis by releasing important mediators like Cytochrome C 
and Apoptosis inducing factor (AIF) [5]. Mitochondria have a strong capacity to sequester 
cytosolic calcium mainly due to electrochemical gradient and Ca2+ uniporter present in its 
inner membrane. Under normal physiological conditions, mitochondria regulate Ca2+ 
homeostasis by acting as a cytosolic Ca2+ buffer [6–8]. Mitochondrial uptake of Ca2+ 
beyond a critical level signals opening of the mitochondrial permeability transition pore 
(mPTP) leading to a series of events including breached mitochondrial permeability, lowered 
ATP, increased ROS, eventually causing cell death via apoptosis or necrosis [6, 9]. As ETC 
involves transfer of electrons through numerous electron carriers, mitochondria are the major 
contributor of reactive oxygen species (ROS) [10]. Leakage of single electrons during the 
electron transfer process causes a reduction of molecular oxygen (O2) leading to the 
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generation of a primary ROS entity called superoxide radicals (O2·−). The primary sites 
within the ETC that contribute to generation of ROS are Complex I and Complex III [10, 
11]. O2·− is highly reactive, but under physiological conditions it is typically rapidly reduced 
further to H2O2 by the enzyme Superoxide dismutase (SOD) [12].
1.2 Introduction to Traumatic Brain Injury
Traumatic brain injury [13] is defined as an insult to the brain caused by an external physical 
force, leading to an alteration in brain functioning [14]. The Centers for Disease Control and 
Prevention estimates that at least 1.7 million cases of TBI occur in the United States 
annually [15], and is steadily on the rise. Currently, approximately 3.2 and 5.3 million 
people live with long-term disabilities as a result of TBI. Furthermore, it has been estimated 
that TBIs contribute to approximately 30.5% of all injury-related deaths [15]. TBI is 
considered a leading cause of death and long-term disability worldwide and affects all age 
groups and genders; however, children and the elderly are often considered at a higher risk 
of experiencing a TBI [16]. Military personnel are also considered to be at a higher risk for 
sustaining TBI, with the Department of Defense reporting over 235,000 service members 
between 2000 and 2011 diagnosed with a TBI [17].
The initial insult can be the result of blunt trauma, penetrating injury (bullet wound), 
acceleration-deceleration, or blast waves injuries [18]. The leading cause of TBI-related 
death occurs from motor vehicle accidents, suicide or falls [19]. The result of these impacts 
varies highly from patient to patient, and is dependent on location of injury, and has been 
correlated with injury severity. The severity of a TBI is classified from mild to severe based 
on the Glascow Coma scale. While the intracranial location and severity of injury contribute 
to the extent of functional deficits, there are also likely contributions from physiological 
changes that occur during hours to months after injury. The progression of molecular 
changes following TBI leads to multiple physiological changes including: mitochondrial 
dysfunction, neuronal degeneration, inflammation, blood-brain barrier (BBB) dysfunction, 
and edema formation [20, 21]. These changes in the cellular microenvironment contribute to 
the secondary injury phase when neuronal loss either permanently disables victims, 
decreasing their quality of life, or results in death.
Despite the tremendous effort invested in TBI research, the ability to minimize chronic 
neurological deficits in TBI patients has remained extremely limited. This is likely a result 
of the vast complexity of the pathophysiology of a TBI. As such, it is necessary to continue 
to explore and understand the underlying mechanisms of a TBI, and how these mechanisms 
relate to functional outcomes.
1.3 Mitochondria & TBI
It has become increasingly clear that TBI, as well as other neurological disorders, are the 
cause or effect of mitochondrial dysfunction [6, 22–31]. Secondary injury following TBI is 
initiated by a massive depolarization of the plasma membrane by voltage- dependent Na+ 
channels. Along with glutamate release, this depolarization causes a massive Ca2+ influx 
into the cell which can activate many damaging cellular enzymes within the cytosol, and as 
such must be sequestered by intracellular organelles, mainly the mitochondria [25, 32, 33]. 
Vekaria et al. Page 3
Neurochem Int. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
After Ca2+ is sequestered into mitochondria via membrane potential- driven transporters, it 
is stored as a Ca2+ phosphate compound within the matrix, causing the matrix to have an 
almost gel-like consistency [25].
The Ca2+ buffering capacity of mitochondria is finite and eventually the Ca2+ influx 
becomes too great, resulting in mitochondrial dysfunction and subsequent initiation of cell 
death pathways [6, 24, 34, 35]. This causes the mitochondria and the cell to swell and 
eventually burst, which are characteristic signs of necrotic cell death [6, 25]. It is also 
important to note that inhibition of mitochondrial Ca2+ uptake by reducing membrane 
potential (ΔΨ) (chemical uncoupling) following TBI is neuroprotective, emphasizing the 
pivotal role of mitochondrial Ca2+ uptake in neuronal cell death following TBI [36–38].
The formation of the mPTP results in mitochondrial dysfunction and has been shown to 
occur after acute TBI and excitotoxic insult [6, 25, 39]. It has been repeatedly shown that 
cyclosporine A [40] (and CsA analogs) inhibits opening of the mPTP and reduce neuronal 
cell death following TBI homeostasis [39, 41–45]. Specifically, NIM811, a non-
immunosuppressive CsA analog, at 10 mg/kg improves tissue sparing, mitochondrial 
functionality, and reduces 4-HNE levels following TBI [44]. Recently, it has also been 
shown that CsA improves respiration by targeting the more damaged synaptic mitochondria, 
relative to non-synaptic mitochondria [46]. In clinical studies, CsA has been demonstrated to 
improve outcome in dose-escalation studies with treatment initiated within 8 hrs post-injury 
but in a second phase II study, which included a broader 12 hr post-injury therapeutic 
window, no evidence of efficacy was demonstrated [47, 48]. These lines of evidence point to 
mitochondria as a valid, therapeutic target following TBI.
1.4 Methylene blue
Methylene Blue (MB), also known as methylthioninium chloride, is a cationic thiazine that 
contains a tri-heterocyclic thiazine ring structure (S(C6H4)2NH4). It was discovered and 
synthesized in the late 1880 by Heinrich Caro, and has been applied widely as a dye, redox 
indicator, and medication [49–51]. The pharmacological use of MB began in 1890s when 
Nobel laureate Paul Ehrlich discovered its usefulness in treating malaria [52]. He noted that 
MB was selectively taken up by the nervous tissue, and the term “magic bullet” was coined 
by this phenomenon. Since then, MB has been used in humans safely for over 120 years to 
treat variety of diseases, including methemoglobinemia, urinary tract infection, nitric oxide-
induced hypotensive complications from septic shock, cardiopulmonary bypass, and in 
diagnostic procedures and Vasoplegic syndrome [53–55] [56–59]. It is also an antidote to 
cyanide and carbon monoxide poisoning [60], and shows neuroprotective property for 
stroke, Parkinson’s disease, Alzheimer’s disease, and optic neuropathy [61–64].
In recent studies, MB was found to be able to improve mitochondrial functions [65]. 
Specifically, MB can function as an alternative electron carrier that efficiently shuttles 
electrons between NADH (mitochondrial complex I) and cytochrome c (complex IV). This 
process reroutes electron transfer upon complex I/III inhibition, reduces electron leakage, 
increase mitochondrial oxidative phosphorylation, and attenuates reactive oxygen species 
(ROS) overproduction under pathological conditions. Through this shunt, MB causes an 
increase in cellular oxygen consumption and a corresponding decrease in anaerobic 
Vekaria et al. Page 4
Neurochem Int. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
glycolysis in vitro and in vivo [66–68]. In addition, chronic exposure to MB results in 
increased activity and expression of mitochondria complex IV [65, 69]. It is therefore has 
been proposed as a metabolic enhancer that attenuates neurodegeneration induced by 
metabolic challenge [64, 70].
1.5 Methylene Blue in CNS injury models
Recently there has been resurgence in the study of MB in diseases related to the central 
nervous system. This is in part due to MBs rapid ability to cross the blood brain barrier 
following intravenous injection, where the concentration in the brain rapidly (less than 1 
hour) reaches 20 times that of plasma[71]. Further, as it is an FDA approved medication, its 
safety profile has already been determined, as well as the optimal clinical dose to use in 
humans. Preclinical research has suggested a potential neuroprotective effect following the 
administration of MB in various CNS injury models including Parkinson’s Disease, 
Alzheimer’s Disease, amyotrophic lateral sclerosis, ischemic stroke, and more recently in 
traumatic brain injury [64]. The common theme in the use of MB in these conditions is their 
link to deficits in mitochondrial function.
Mitochondria are sensitive to changes in the physiological state of a cell, and their 
dysfunction has been implicated in numerous neuropathological diseases, including TBI. 
Increasing evidence suggests that TBI leads to both direct mechanical damage and 
functional disturbances in mitochondria and plays a key role in contributing to apoptotic and 
necrotic cell death. As the brain is a highly aerobic, energy-demanding tissue, an imbalance 
in energy demand for repair of cellular damage and concomitant decrease in energy 
generation caused by mitochondrial dysfunction leads to increased cellular damage. 
Excitotoxicity, production of reactive oxygen species (ROS), Ca2+ overload, apoptosis-
inducing factor, and caspases are some of the primary candidates that induce mitochondrial 
damage following TBI [72–74]. During injury, the surge in ROS facilitates a vicious cycle 
that accelerates mitochondrial damage, excitotoxicity, lipid peroxidation, and inflammation 
[75]. Mitochondrial membrane potential is a key indicator of damage to the mitochondria 
and may be linked to early-stage apoptosis. Thus, mitochondrial targeting strategies in 
stroke, ischemia and TBI have been increasingly studied, as their maintenance could 
potentially preserve brain function [76, 77].
In normal rats a single low-dose of MB has significant effects on CBF, metabolism, and 
fMRI responses [70]. MB also increases global glucose uptake, oxygen consumption, CBF 
[70], and fMRI responses [78] in normal rats, but has no significant effects on heart rate, 
respiration rate, or blood pressure. MB has been demonstrated to be effective at reducing 
lesion volume, vasogenic edema formation, function deficits and neurodegeneration in a 
cortical impact model of TBI in rats [79, 80]. In these studies MB was administered 1 and 3 
hours25 or 24 hours24 after TBI. In the vehicle group, the lesion volume peaked at 2 days 
and decreased at 14 days post TBI. In the MB group, by contrast, the lesion volume did not 
change substantially with time and was significantly smaller than the vehicle group at all 
time points studied.
The objective of this paper was to determine the in vitro effects of MB on mouse cortex 
mitochondrial bioenergetics and reactive oxygen species production. We hypothesized that 
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MB treatment would improve mitochondrial bioenergetics, and decrease the production of 
reactive oxygen species. To test this hypothesis mitochondria were isolated from mouse 
cortex and further purified and separated into synaptic and nonsynaptic fractions. The 
fractions were then treated with a range of doses of MB and mitochondrial bioenergetics and 
production of H2O2 were measured.
2. Materials and Methods
2.1 Isolation of mitochondria from the mouse cortex
All animal experimental protocols were approved by the University of Kentucky Animal 
Use and Care Committee and complied with National Institutes of Health guide for the care 
and use of Laboratory animals. Mitochondrial isolation protocol was adapted from the 
previously described protocols with modifications [81–83]. All the steps were carried out at 
4°C or on ice. Briefly 6–8 week old male C57BL/6 mice (n=10; 20–22 g) were euthanized 
with CO2 and the cortex was dissected out and homogenized using Teflon-glass dounce 
homogenizer containing isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 
mM HEPES, 1 mM EGTA, Adjusted pH 7.2 with KOH). The homogenate was transferred to 
2ml micro centrifuge tube and spun at 1300 × g for 3 minutes. The supernatant was further 
transferred in a fresh 2ml micro centrifuge tube and spun at 13,000 × g for 10 minutes. The 
supernatant was discarded and the crude mitochondrial pellet was resuspended in 500μL of 
isolation buffer. For all experiments biological n=4 to 6 and technical replicates n≥3.
2.2 Separation and purification of Synaptic and Non-synaptic mitochondria
The mitochondrial fraction was further purified and separated into synaptic and nonsynaptic 
fractions using double layered discontinuous Ficoll density gradient centrifugation [84]. 
Ficoll stock (20% Ficoll, 0.3M Sucrose, 10mM Tris and 0.2mM EGTA) was diluted using 
isolation buffer to make 7.5% and 10% Ficoll solution. The double layer Ficoll gradient was 
prepared using 2ml each of 7.5% Ficoll layered over 10% Ficoll solution. The mitochondrial 
suspension was layered on top of the gradient and was centrifuged at 100,000 ×g for 30 min 
using ultracentrifuge to get neurosynaptosomes and non-synaptic mitochondria. Based on 
density difference, the neurosynaptosomes were collected from the interface of the two 
Ficoll layers and non-synaptic mitochondria were collected from the pellet. The 
neurosynaptosomal fraction was transferred into a 2 ml centrifuge tube and 4X diluted with 
isolation buffer and centrifuged at 13,000 ×g for 10 min. The neurosynaptosomal pellet was 
resuspended in 400 μl of isolation buffer and the synaptic mitochondria were released using 
a pressurized nitrogen cell disruptor at 1200 psi for 10 min at 4 °C. The synaptic 
mitochondria were again purified using Ficoll purification steps as done before. This time 
synaptic mitochondria released from synaptosomes were collected from the pellet. Both 
non-synaptic and synaptic mitochondrial pellets from the two ultracentrifugation steps were 
resuspended in 600 μl of EGTA-free isolation buffer and were pelleted at 10,000 × g for 10 
min at 4 °C. The supernatants were discarded and the synaptic and non-synaptic 
mitochondrial pellets were resuspended in EGTA-free isolation buffer to get ~10ug/ul 
approximate concentration of mitochondria. The absolute protein concentration was 
determined using BCA protein assay kit (Pierce, Cat # 23227) by recording absorbance at 
560 nm on Biotek Synergy HT plate reader (Winooski, Vermont).
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2.3 Mitochondrial bioenergetics measurements
The mitochondrial bioenergetic measurements in the presence of varying concentrations of 
Methylene Blue (0.0001 μg/ml to 10 μg/ml were carried out using a Seahorse XFe24 
Extracellular Flux Analyzer (Agilent Technologies, USA). It determines the bioenergetics of 
mitochondria by measuring the Oxygen Consumption Rates (OCR) during various states of 
respiration. The OCR were measured in the presence of different substrates, inhibitors and 
uncouplers of Electron Transport Chain (ETC) using previous methods with slight 
modifications [84–88]. The stocks used for the assays are 500 mM pyruvate, 250 mM 
malate, and 30 mM adenosine diphosphate (ADP), and 1 M succinate (pH for all were 
adjusted to 7.2) plus assay solutions of 1 mg/mL (1.26 mM) oligomycin A, 1 mM carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), 1 mM rotenone were prepared in 
ethanol. As per the instructions from XFe24 Extracellular Flux kit, the sensor cartridge was 
hydrated and kept at 37 °C overnight before the experiment. The injection ports A to D of 
the sensor cartridge were loaded with 75ul of different combinations of the above substrates/
inhibitors/uncouplers as follows. Before loading, the stocks were diluted appropriately in the 
respiration buffer (RB) (215 mM mannitol, 75 mM sucrose, 0.1 % BSA, 20 mM HEPES, 2 -
M MgCl2, and 2.5 mM KH2PO4, Adjusted pH 7.2) to get the final concentrations in the 
respiration chamber of 5 mM pyruvate, 2.5 mM malate and 1 mM ADP (via Port A), 1 μM 
oligomycin A (via Port B). 4 μM FCCP (via Port C) and 0.1 μM rotenone and 10 mM of 
succinate (via Port D) starting with the initial volume of 525ul RB in the chamber and 
diluting it to 9X, 10X, 11X and 12X with every injection through ports A to D respectively. 
Once loaded, the sensor cartridge was placed into the Seahorse XFe24 Flux Analyzer for 
automated calibration.
Seahorse Standard XF24 assay plates were used separately for loading mitochondria. 
Initially the purified synaptic and non-synaptic mitochondria were diluted to 2.5 μg/50ul in 
RB and 50 μl was loaded in each well resulting in 2.5 μg mitochondria/well. The assay 
plates were centrifuged at 3000 rpm for 4 minutes at 4°C to adhere the mitochondria at the 
bottom of the wells. After centrifugation, 475 μL RB (pre-incubated to 37°C) was added 
without disturbing the mitochondrial layer to obtain a final volume of 525 μL per well. After 
the instrument calibration with the sensor cartridge was complete, the utility plate was 
replaced by the plate loaded with mitochondria for bioenergetics analysis.
The assays were carried out under previously optimized protocol. [88]. Briefly, it involved 
cyclic steps of mixing, sequential injections of substrates/inhibitors via Ports A thru D, 
mixing, equilibration, and measurement of the OCR and pH through fluorimetric optical 
probes. The data output gives State III respiration in the presence of pyruvate, malate and 
ADP (Port A) followed by State IV rate in presence of oligomycin A (Port B). Sequentially, 
it gives uncoupled Respiration State VPM (State V1) and State VSucc (State V2) in the 
presence of FCCP (Port C) and rotenone plus succinate (Port D) respectively.
2.4 Mitochondrial H2O2 production
The H2O2 generated by actively respiring mitochondria was measured using Amplex Red 
Hydrogen Peroxide/Peroxidase Assay Kit (molecular probes, Cat#A22188) using a 96-well 
plate format. In a 130μl assay system, a series of MB concentrations from 0.0001 μg/ml to 1 
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μg/ml were prepared along with the combinations of mitochondrial substrates (Final 
concentrations 5 mM pyruvate, 2.5 mM malate and 150 μM ADP, 1 μM oligomycin A. 4 μM 
FCCP and 0.1 μM rotenone and 10 mM of succinate) prepared in Respiration buffer (RB 
mentioned in the OCR measurement protocol). The plate was placed in the 37°C pre-
incubated plate reader (Biotek Synergy HT plate reader, Winooski, Vermont) and 25μl (5X) 
of Amplex solution (125μM Amplex + 0.5U/ml HRP) prepared in RB was added to each 
well using automated injectors. The fluorescence was measured at one-minute intervals at 
the wavelengths λEX 571 and λEM 585. The relative H2O2 generated was calculated from 
the difference in the fluorescence measurements.
2.5 Statistical Analysis
For all statistical comparisons, significance was set at p ≤ 0.05. OCR and ROS data were 
analyzed using a one-factor analysis of variance (ANOVA) followed by post-hoc analysis 
(Dunnett test) when warranted.
3 Results and Discussion
3.1 Effect of MB on brain mitochondrial bioenergetics
The in vitro effects of MB on mouse cortex mitochondrial bioenergetics were assessed by 
exposing them to different concentrations of MB ranging from 0.0001μg/ml to 10μg/ml in 
respiration buffer just before initiating OCR measurements on seahorse XFe24 (Figures 1 
and 2). The dose range of MB was chosen based on previous studies in vitro and in vivo [66, 
67, 89, 90]. Dosages above 7mg/kg are considered cytotoxic [63, 91]. The synaptic and non-
synaptic mitochondria showed varied sensitivity to MB. In both, the state III levels showed a 
nonsignificant surge at 0.0001μg/ml. With increasing concentrations non-synaptic 
mitochondria were more sensitive to MB compared to synaptic with a significant drop in 
state III at 0.01μg/ml of MB, whereas the synaptic mitochondria failed to show a significant 
decrease in state III respiration even at 1μg/ml. There was a sharp drop in the OCR at 
10μg/ml of MB in both synaptic and non-synaptic mitochondria. In both, there were no 
significant increases in state IV respiration at the lower concentrations of MB till 0.1μg/ml, 
but both the mitochondrial populations demonstrated a significant increase in State IV at 
1μg/ml which declined at the highest concentration (10μg/ml), indicating a complete 
shutdown of mitochondrial respiration. Respiration Control Ratio [92] which is an important 
indicator of mitochondrial uncoupling remained unchanged in non-synaptic mitochondria 
until 0.1μg/ml whereas the synaptic mitochondria showed a significant decrease in the 
uncoupling activity even at 0.001μg/ml of MB (Figure 1 and 2). State VPM, which indicates 
Complex I mediated uncoupled respiration showed a response similar to that of State III in 
both mitochondrial populations but was significant only at the higher dose of 10μg/ml of 
MB. There was no major change in State Vsucc, a complex II mediated uncoupled respiration 
in either population of mitochondria, indicating that MB is interrupting mitochondrial 
respiration mainly through Complex I and uncoupling mechanisms. The overall results 
suggest that MB has a varied response to both synaptic and non-synaptic mitochondrial 
populations. In case of non-synaptic, MB is targeting respiratory complex I directly causing 
a suppression of respiration, but has less effect on the RCR. In comparison, synaptic 
mitochondrial complex I is less sensitive to MB but there was significant uncoupling as 
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indicated by the drop in RCR. This seems to indicate basic differences exist between the two 
mitochondrial populations and their response to external redox stimuli like MB. It should be 
noted that the lack of effect on complex-II driven OCR at concentrations that completely 
shut down complex-I driven respiration in either population of mitochondria is in contrast to 
the proposed site of action for MB which is hypothesized to be upstream at complex III. 
These data seem to indicate that at higher concentrations, MB is altering mitochondrial 
respiration at some target that has yet to be elucidated.
3.2 ROS production in respiring mitochondria
Mitochondrial ROS generation was measured in terms of H2O2 production using Amplex 
assay. As discussed earlier, mitochondria are a major source of ROS and H2O2 generation 
was measured in actively respiring mitochondria using specific substrates and inhibitors. 
This was done to induce maximum ROS production (in presence of oligomycin) and 
minimal ROS (presence of FCCP) under control conditions. Looking at the control data of 
synaptic and non-synaptic mitochondria (Figure), compared to starved mitochondria 
(Baseline), under respiring conditions in the presence of PM (pyruvate/malate) and ADP 
(state II and III respiration respectively), there was a sharp increase in the H2O2 generation 
due to activation of ETC (Figure 3 and 4). State IV respiration, in the presence of 
Oligomycin, an inhibitor of ATPase, generates a high electric potential difference across the 
inner mitochondrial membrane resulting in more slippage of electrons and results in 
increased ROS production. Under state V respiration in the presence of FCCP due to 
uncoupling of mitochondria the H2O2 production returns to the baseline levels. In the 
presence of rotenone (state V) there is an increase in the ROS generation even in the relaxed 
state as rotenone is known to inhibit complex I, and release free electrons from complex I. 
This H2O2 production remained unaffected even in the presence of succinate because in the 
uncoupled state there is a minor contribution of complex II mediated respiration to the ROS 
generation.
3.3 Effect of MB on mitochondrial ROS production
MB showed similar effects on synaptic and non-synaptic mitochondrial ROS production 
measured in the form of H2O2 production (Figure 3 and 4). Although both mitochondrial 
populations showed similar responses, overall the synaptic mitochondria showed slightly 
higher H2O2 production compared to non-synaptic in the presence of MB (given the effects 
of 10μg/ml MB on respiration, we did not assess its effect on ROS production). In both 
populations, there was no significant change observed in ROS production until 0.01μg/ml of 
MB under most of the conditions. However, there was a significant increase in H2O2 at 0.1 
and 1μg/ml of MB. In this range MB affects mitochondrial respiration irrespective of the 
coupled or uncoupled state, but to varied extents. At the high concentration of 1μg/ml, MB 
showed a maximum rise in H2O2 generation which is consistent with the state III and state 
IV alterations in OCR measurements. Considering the fold change in the production of ROS 
for each individual state, State III (ADP) and State V (FCCP), where there is maximum flow 
of electrons thru the ETS, showed the maximum fold change in H2O2 production compared 
to their respective controls with no MB. This suggests that at high concentrations, MB may 
be directly releasing/donating free electrons irrespective of the mitochondrial membrane 
potential.
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4. Discussion and Conclusions
Following a TBI, the body seems to enter a state of metabolic crisis, mitochondrial 
dysfunction become apparent, oxidative stress increases and a dysregulation of excitatory 
amino acids occurs rapidly. Mitochondrial dysfunction is a well-documented hallmark of 
traumatic CNS injury and strategies that target this dysfunction have been experimentally 
successful. This indicates that targeting mitochondrial dysfunction following a brain injury 
is not only a well hypothesized target but a valid target both in the laboratory and the clinic. 
One such compound is Methylene Blue, which has been studied for over 100 years and can 
function as an alternative electron carrier to shuttle electrons between mitochondrial 
complex I and cytochrome c and has shown promise in experimental models of TBI. Our 
current results demonstrate that Methylene Blue alters mitochondrial bioenergetics 
differently depending on the compartmental source of the mitochondria (synaptic vs non-
synaptic) by inhibiting respiration at complex I or upstream of complex I in non-synaptic 
mitochondria. However, Methylene Blue was demonstrated to increase mitochondrial ROS 
production regardless of the mitochondrial source in a dose dependent manner. Granted, our 
studies employed well-coupled mitochondria isolated from experimental naïve animals and 
that future work should examine the effect of this compound on mitochondria isolated from 
TBI animals or using ex vivo bioenergetics stressors. At face value, these data would seem 
to indicate that a fine line exists in the utilization of Methylene Blue to promote 
mitochondrial function and that care should be taken to generate rigorous dose-response 
curves for this compound. Alternatively, these data could point to other neuroprotective 
mechanisms being utilized by Methylene Blue, including activation of endogenous 
antioxidant systems such as Nrf2 by increasing mitochondrial ROS production, or perhaps 
by increasing mitochondrial biogenesis by reducing mitochondrial respiration [93]. 
Regardless, Methylene Blue offers a valid approach to reduce the effects of bioenergetics 
failure following TBI and may still prove to be a “magic bullet”.
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Highlights
• Mitochondrial play a pivotal role in determining neuronal cell survival and 
outcome following traumatic brain injury (TBI).
• Strategies that target mitochondrial dysfunction following TBI have proven to 
be neuroprotective.
• Methylene Blue (MB) is one relatively new TBI therapeutic approach that 
may be targeting mitochondrial dysfunction.
• MB alters mitochondrial function differentially in synaptic vs non-synaptic 
brain mitochondria including shutting down mitochondrial respiration and 
increasing ROS production.
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Figure 1. Effect of Methylene Blue on cortical non-synaptic mitochondrial respiration
Mitochondrial bioenergetics were assessed in the presence of varying concentrations of 
Methylene Blue (0.0001 μg/ml to 10 μg/ml) during classic states of respiration (III – V) and 
RCRs calculated. (PM=pyruvate/malate; SUCC=succinate in presence of rotenone) *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 compared to control. Bars are mean ± SD.
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Figure 2. Effect of Methylene Blue on cortical synaptic mitochondrial respiration
Mitochondrial bioenergetics were assessed in the presence of varying concentrations of 
Methylene Blue (0.0001 μg/ml to 10 μg/ml) during classic states of respiration (III – V) and 
RCRs calculated. (PM=pyruvate/malate; SUCC=succinate in presence of rotenone) *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 compared to control OCR. Bars are mean ± SD.
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Figure 3. Effect of Methylene Blue on cortical non-synaptic mitochondrial ROS production
Mitochondrial ROS production was measured using the H2O2 indicator Amplex Red under 
various states of respiration (PM-pyruvate/malate, ADP, Oligo-Oligomycin, FCCP, Rot-
Rotenone, Succ-Succinate) and with and without MB (0.0001 μg/ml to 1 μg/ml). *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 compared to control fluorescence (FU). Fold change 
is plotted in the lower panel. Bars are mean ± SD.
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Figure 4. Effect of Methylene Blue on cortical synaptic mitochondrial ROS production
Mitochondrial ROS production was measured using the H2O2 indicator Amplex Red under 
various states of respiration (PM-pyruvate/malate, ADP, Oligo-Oligomycin, FCCP, Rot-
Rotenone, Succ-Succinate) and with and without MB (0.0001 μg/ml to 1 μg/ml). *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 compared to control fluorescence (FU). Fold change 
is plotted in the lower panel. Bars are mean ± SD.
Vekaria et al. Page 19
Neurochem Int. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
